Metformin is the most common anti-diabetic drug and a promising therapy for disorders beyond diabetes, including Rett syndrome (RTT), a rare neurologic disease characterized by severe intellectual disability. A 10-day-long treatment rescued aberrant mitochondrial activity and restrained oxidative stress in a female RTT mouse model. However, this treatment regimen did not improve the phenotype of RTT mice. In the present study, we demonstrate that a 4-month-long treatment with metformin (150 mg/Kg/day, delivered in drinking bottles) provides a selective normalization of cognitive flexibility defects in RTT female mice at an advanced stage of disease, but it does not affect their impaired general health status and abnormal motor skills. The 4-month-long treatment also rescues the reduced activity of mitochondrial respiratory chain complex activities, the defective brain ATP production and levels as well as the increased production of reactive oxidizing species in the whole blood of RTT mice. A significant boost of PGC-1α-dependent pathways related to mitochondrial biogenesis and antioxidant defense occurs in the brain of RTT mice that received the metformin treatment. Further studies will have to verify whether these effects may underlie its long-lasting beneficial effects on brain energy metabolism.

Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome / Urbinati, Chiara; Lanzillotta, Chiara; Cosentino, Livia; Valenti, Daniela; Quattrini, Maria Cristina; Di Crescenzo, Livia; Prestia, Francesca; Pietraforte, Donatella; Perluigi, Marzia; Di Domenico, Fabio; Vacca, Rosa Anna; De Filippis, Bianca. - In: NEUROPHARMACOLOGY. - ISSN 1873-7064. - 224:(2023), p. 109350. [10.1016/j.neuropharm.2022.109350]

Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome

Urbinati, Chiara;Lanzillotta, Chiara;Valenti, Daniela;Prestia, Francesca;Perluigi, Marzia;Di Domenico, Fabio;
2023

Abstract

Metformin is the most common anti-diabetic drug and a promising therapy for disorders beyond diabetes, including Rett syndrome (RTT), a rare neurologic disease characterized by severe intellectual disability. A 10-day-long treatment rescued aberrant mitochondrial activity and restrained oxidative stress in a female RTT mouse model. However, this treatment regimen did not improve the phenotype of RTT mice. In the present study, we demonstrate that a 4-month-long treatment with metformin (150 mg/Kg/day, delivered in drinking bottles) provides a selective normalization of cognitive flexibility defects in RTT female mice at an advanced stage of disease, but it does not affect their impaired general health status and abnormal motor skills. The 4-month-long treatment also rescues the reduced activity of mitochondrial respiratory chain complex activities, the defective brain ATP production and levels as well as the increased production of reactive oxidizing species in the whole blood of RTT mice. A significant boost of PGC-1α-dependent pathways related to mitochondrial biogenesis and antioxidant defense occurs in the brain of RTT mice that received the metformin treatment. Further studies will have to verify whether these effects may underlie its long-lasting beneficial effects on brain energy metabolism.
2023
Cognition; metformin; mitochondria; oxidative stress status; Rett syndrome
01 Pubblicazione su rivista::01a Articolo in rivista
Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome / Urbinati, Chiara; Lanzillotta, Chiara; Cosentino, Livia; Valenti, Daniela; Quattrini, Maria Cristina; Di Crescenzo, Livia; Prestia, Francesca; Pietraforte, Donatella; Perluigi, Marzia; Di Domenico, Fabio; Vacca, Rosa Anna; De Filippis, Bianca. - In: NEUROPHARMACOLOGY. - ISSN 1873-7064. - 224:(2023), p. 109350. [10.1016/j.neuropharm.2022.109350]
File allegati a questo prodotto
File Dimensione Formato  
Urbinati_Chronic_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4.23 MB
Formato Adobe PDF
4.23 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1669730
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact